F1Shares of common stock, par value $0.0001 per share (the "Common Shares") of Cidara Therapeutics, Inc. (the "Issuer") are held directly by Seachaid Pharmaceuticals, LLC. ("Seachaid").
F2Shares of preferred stock, par value $0.0001 per share (the "Preferred Shares") are convertible at any time, at the holder's election, and have no expiration date. Upon the consummation of the Issuer's initial public offering, the Preferred Shares will automatically convert into Common Shares on a 25.4-to-1 basis.
F3The Preferred Shares are directly held by Aisling Capital II, LP ("Aisling").
F4The investment committee of Aisling holds sole voting and dispositive power over the Common Shares held by Seachaid and the Preferred Shares held by Aisling. Aisling is a majority-owner of Seachaid. Aisling Capital Partners LP ("Aisling GP") is the general partner of Aisling and Aisling Capital Partners LLC ("Aisling Partners") is the general partner of Aisling GP. The individual managing members (collectively, the "Managers") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling and Seachaid. (Cont'd in FN5)
F5(Cont'd from FN4) Each of the Reporting Persons disclaims beneficial ownership of the Common Shares and Preferred Shares, except to the extent of such person's pecuniary interest. Mr. Elms has filed a separate Form 3 with respect to his beneficial ownership of the Common Shares and Preferred Shares. Following the closing of the Issuer's initial public offering, the Reporting Persons will no longer own more than 10% of the Issuer's Common Shares.